These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 31547836)

  • 1. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma.
    Yin Z; Dong C; Jiang K; Xu Z; Li R; Guo K; Shao S; Wang L
    J Hematol Oncol; 2019 Sep; 12(1):101. PubMed ID: 31547836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma.
    Akkız H
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p.
    Yugawa K; Yoshizumi T; Mano Y; Itoh S; Harada N; Ikegami T; Kohashi K; Oda Y; Mori M
    Eur J Surg Oncol; 2021 Feb; 47(2):384-393. PubMed ID: 32883551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma cells remodel the pro-metastatic tumour microenvironment through recruitment and activation of fibroblasts via paracrine Egfl7 signaling.
    Sun B; Lei X; Cao M; Li Y; Yang LY
    Cell Commun Signal; 2023 Jul; 21(1):180. PubMed ID: 37480091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.
    Zhou Z; Hu Y; Wu Y; Qi Q; Wang J; Chen L; Wang F
    Mol Immunol; 2022 Nov; 151():218-230. PubMed ID: 36179604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.
    Mano Y; Yoshio S; Shoji H; Tomonari S; Aoki Y; Aoyanagi N; Okamoto T; Matsuura Y; Osawa Y; Kimura K; Yugawa K; Wang H; Oda Y; Yoshizumi T; Maehara Y; Kanto T
    J Gastroenterol; 2019 Nov; 54(11):1007-1018. PubMed ID: 30941514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated fibroblasts promote the stemness of CD24
    Li Y; Wang R; Xiong S; Wang X; Zhao Z; Bai S; Wang Y; Zhao Y; Cheng B
    J Mol Med (Berl); 2019 Feb; 97(2):243-255. PubMed ID: 30564864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-Associated Fibroblast-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression.
    Song M; He J; Pan QZ; Yang J; Zhao J; Zhang YJ; Huang Y; Tang Y; Wang Q; He J; Gu J; Li Y; Chen S; Zeng J; Zhou ZQ; Yang C; Han Y; Chen H; Xiang T; Weng DS; Xia JC
    Hepatology; 2021 May; 73(5):1717-1735. PubMed ID: 33682185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Versican Secreted by Cancer-Associated Fibroblasts is a Poor Prognostic Factor in Hepatocellular Carcinoma.
    Kato K; Fukai M; Hatanaka KC; Takasawa A; Aoyama T; Hayasaka T; Matsuno Y; Kamiyama T; Hatanaka Y; Taketomi A
    Ann Surg Oncol; 2022 Oct; 29(11):7135-7146. PubMed ID: 35543908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblasts in hepatocellular carcinoma.
    Kubo N; Araki K; Kuwano H; Shirabe K
    World J Gastroenterol; 2016 Aug; 22(30):6841-50. PubMed ID: 27570421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma.
    Ma LJ; Wang XY; Duan M; Liu LZ; Shi JY; Dong LQ; Yang LX; Wang ZC; Ding ZB; Ke AW; Cao Y; Zhang XM; Zhou J; Fan J; Gao Q
    J Pathol; 2017 Dec; 243(4):407-417. PubMed ID: 28833123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma.
    Baglieri J; Brenner DA; Kisseleva T
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POSTN
    Wang H; Liang Y; Liu Z; Zhang R; Chao J; Wang M; Liu M; Qiao L; Xuan Z; Zhao H; Lu L
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39067872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway.
    Chen S; Morine Y; Tokuda K; Yamada S; Saito Y; Nishi M; Ikemoto T; Shimada M
    Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195849
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Long F; Zhong W; Zhao F; Xu Y; Hu X; Jia G; Huang L; Yi K; Wang N; Si H; Wang J; Wang B; Rong Y; Yuan Y; Yuan C; Wang F
    Theranostics; 2024; 14(12):4822-4843. PubMed ID: 39239526
    [No Abstract]   [Full Text] [Related]  

  • 16. Spatial multiomics reveals a subpopulation of fibroblasts associated with cancer stemness in human hepatocellular carcinoma.
    Jing SY; Liu D; Feng N; Dong H; Wang HQ; Yan X; Chen XF; Qu MC; Lin P; Yi B; Feng F; Chen L; Wang HY; Li H; He YF
    Genome Med; 2024 Aug; 16(1):98. PubMed ID: 39138551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy.
    Yin Z; Jiang K; Li R; Dong C; Wang L
    Mol Cancer; 2018 Dec; 17(1):178. PubMed ID: 30593276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming.
    Wang H; Liu F; Wu X; Zhu G; Tang Z; Qu W; Zhao Q; Huang R; Tian M; Fang Y; Jiang X; Tao C; Gao J; Liu W; Zhou J; Fan J; Wu D; Shi Y
    Exp Cell Res; 2024 Feb; 435(2):113947. PubMed ID: 38301989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
    J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.